NCT05514106
MIBG in Aging and Neurologic Disorders
Enrolling by Invitation
PHASE4Ages 40–90InterventionalDiagnosticMayo ClinicInvestigator-initiated
~50 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:meta-iodobenzylguanidine (MIBG) (123I)123I-MIBG scintigraphy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Correlate myocardial 123I-MIBG scintigraphy findings
Measured over 10 years
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Bradley Boeve, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Diagnosis of one of the syndromes/diagnoses of interest using established criteria
STMS score above 10
No active medical disorder that could preclude participation
Stable medication regimen over previous four weeks
Absence of certain medications that could significantly impact the myocardial 123I-MIBG scintigraphy findings
For those with dementia, caregiver that is with the patient at least 4 hours/day for at least 5 days per week
For those with dementia, or severe parkinsonism, patient and caregiver willing and able to participate in all study-related procedures
Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf.
Exclusion
Does not fulfill criteria for any of the desired diagnoses
Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative
Women who are pregnant or are breast-feeding an infant
STMS score \<10
Active medical disorder that could preclude participation in this protocol
Hypersensitivity to the radioligand or iodine
Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease
Renal disease viewed by the physician to be too severe to warrant myocardial 123I-MIBG scintigraphy imaging
History of significant alcohol or drug abuse
Any other medical disorder considered by the study physicians as inappropriate for enrollment in this protocol
Patient or caregiver unwilling or unable to participate in all study-related procedures
Caregiver is not with a patient with dementia or severe parkinsonism at least 4 hours/day for at least 5 days/week
Patient or caregiver unwilling or unable to provide informed consent
What this trial measures
- Correlate myocardial 123I-MIBG scintigraphy findings10 years
Number of myocardial 123I-MIBG scintigraphy findings to correlate with clinical pathologic diagnosis